Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Jul 18, 2014; 5(3): 188-203
Published online Jul 18, 2014. doi: 10.5312/wjo.v5.i3.188
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty
Garrett B Aikens, Jacob R Osmundson, Michael P Rivey
Garrett B Aikens, Department of Pharmacy, Central Alabama Veterans Health Care System, Montgomery, AL 36109, United States
Garrett B Aikens, Department of Pharmacy Practice, Auburn University Harrison School of Pharmacy, Auburn University, Auburn, AL 36849, United States
Jacob R Osmundson, Michael P Rivey, Department of Pharmacy Practice, University of Montana Skaggs School of Pharmacy, Missoula, MT 59812, United States
Jacob R Osmundson, Michael P Rivey, Department of Pharmacy, Community Medical Center, Missoula, MT 59804, United States
Author contributions: Aikens GB, Osmundson JR and Rivey MP were all involved in the conception and writing of the manuscript.
Correspondence to: Garrett B Aikens, PhD, BCACP, Department of Pharmacy, Central Alabama Veterans Health Care System, Montgomery, Columbus CBOC, 1310 13th Avenue, Columbus, AL 36109, United States. garrett.aikens@va.gov
Telephone: +1-706-2577200 Fax: +1-706-6536645
Received: December 28, 2013
Revised: March 4, 2014
Accepted: May 14, 2014
Published online: July 18, 2014
Core Tip

Core tip: This review focuses on the drug-specific characteristics, efficacy, safety, and economic impact of the target specific oral anticoagulants including dabigatran, rivaroxaban, apixaban, and edoxaban for thromboprophylaxis following total hip arthroplasty, as well as the aspects of therapeutic monitoring and anticoagulation reversal in the event of bleeding complications or a need for urgent reversal.